Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
CLINICAL RESEARCH
From expression to immune responses: exploring the multifaceted roles of CTNNBIP1 in osteosarcoma
1
Department of Pediatric Surgery, Affiliated Maternity and Child Healthcare Hospital of Nantong University, Nantong, Jiangsu Province, China
2
Center of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China
3
Nantong Institute of Genetics and Reproductive Medicine, Affiliated Maternity and Child Healthcare Hospital of Nantong University, Nantong, Jiangsu Province, China
4
Department of Trauma Center, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China
These authors had equal contribution to this work
Submission date: 2025-02-02
Final revision date: 2025-04-03
Acceptance date: 2025-04-19
Online publication date: 2025-07-10
Corresponding author
Zhijun Du
Department of Pediatric Surgery Affiliated Maternity and Child Healthcare Hospital of Nantong University No. 399 Century Avenue Nantong, 226001 Jiangsu Province, China Phone: +86 13813713315
Department of Pediatric Surgery Affiliated Maternity and Child Healthcare Hospital of Nantong University No. 399 Century Avenue Nantong, 226001 Jiangsu Province, China Phone: +86 13813713315
Yang Yang
Department of Trauma Center Affiliated Hospital of Nantong University No. 20 West Temple Road Nantong, 226001 Jiangsu Province, China Phone: +86 13773641251
Department of Trauma Center Affiliated Hospital of Nantong University No. 20 West Temple Road Nantong, 226001 Jiangsu Province, China Phone: +86 13773641251
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The CTNNBIP1 gene has been reported to be involved in development, tumorigenesis, tissue differentiation, and other processes. However, the definite roles of CTNNBIP1 in osteosarcoma remained unclear. Therefore, this study was conducted to explore the roles of CTNNBIP1 in osteosarcoma.
Material and methods:
All data for bioinformatics analysis were acquired from GEO and TARGET osteosarcoma datasets. Survival analysis, expression analysis, Cox regression analyses, nomogram, gene set enrichment analysis (GSEA), and immune evaluations were performed sequentially. Experiments of qRT-PCR, western blot and immunohistochemistry were used to verify the expression of CTNNBIP1 in osteosarcoma.
Results:
The expression of CTNNBIP1 was higher in osteosarcoma than in normal tissues, and further in vitro and in vivo experimental results of qRT-PCR, western blot, and immunohistochemistry remained consistent (all p < 0.05). Both univariate and multivariate Cox regression analyses revealed that disease metastasis status at diagnosis and CTNNBIP1 were independent predictors of OS in osteosarcoma (both p < 0.05). GSEA results indicated that CTNNBIP1 was significantly enriched in three pathways, including B cell receptor and nitrogen metabolism pathways, in osteosarcoma. As for the immunologic roles of CTNNBIP1 in osteosarcoma, CTNNBIP1 was found to be markedly associated with infiltration levels of naïve B cells and resting mast cells and tumor microenvironment (all p < 0.05). Furthermore, the TIDE algorithm indicated that osteosarcoma patients with elevated CTNNBIP1 expression have a better immune response to immunotherapy.
Conclusions:
Our study indicated for the first time that CTNNBIP1 may serve as a potential biomarker of prognosis and immunotherapy for osteosarcoma.
The CTNNBIP1 gene has been reported to be involved in development, tumorigenesis, tissue differentiation, and other processes. However, the definite roles of CTNNBIP1 in osteosarcoma remained unclear. Therefore, this study was conducted to explore the roles of CTNNBIP1 in osteosarcoma.
Material and methods:
All data for bioinformatics analysis were acquired from GEO and TARGET osteosarcoma datasets. Survival analysis, expression analysis, Cox regression analyses, nomogram, gene set enrichment analysis (GSEA), and immune evaluations were performed sequentially. Experiments of qRT-PCR, western blot and immunohistochemistry were used to verify the expression of CTNNBIP1 in osteosarcoma.
Results:
The expression of CTNNBIP1 was higher in osteosarcoma than in normal tissues, and further in vitro and in vivo experimental results of qRT-PCR, western blot, and immunohistochemistry remained consistent (all p < 0.05). Both univariate and multivariate Cox regression analyses revealed that disease metastasis status at diagnosis and CTNNBIP1 were independent predictors of OS in osteosarcoma (both p < 0.05). GSEA results indicated that CTNNBIP1 was significantly enriched in three pathways, including B cell receptor and nitrogen metabolism pathways, in osteosarcoma. As for the immunologic roles of CTNNBIP1 in osteosarcoma, CTNNBIP1 was found to be markedly associated with infiltration levels of naïve B cells and resting mast cells and tumor microenvironment (all p < 0.05). Furthermore, the TIDE algorithm indicated that osteosarcoma patients with elevated CTNNBIP1 expression have a better immune response to immunotherapy.
Conclusions:
Our study indicated for the first time that CTNNBIP1 may serve as a potential biomarker of prognosis and immunotherapy for osteosarcoma.
REFERENCES (46)
1.
Philip T, Blay JY, Brunat-Mentigny M, et al. Osteosarcoma. Br J Cancer 2001; 84 (Suppl 2): 78-80.
2.
Cortini M, Avnet S, Baldini N. Mesenchymal stroma: role in osteosarcoma progression. Cancer Letters 2017; 405: 90-9.
3.
Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 2015; 33: 3029-35.
4.
Meazza C, Scanagatta P. Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther 2016; 16: 543-56.
5.
Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer 2005; 104: 1100-9.
6.
Qi W, Chen J, Cheng X, et al. Targeting the Wnt-regulatory protein CTNNBIP1 by microRNA-214 enhances the stemness and self-renewal of cancer stem-like cells in lung adenocarcinomas. Stem Cells 2015; 33: 3423-36.
7.
Tago K, Nakamura T, Nishita M, et al. Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Develop 2000; 14: 1741-9.
8.
Satoh K, Kasai M, Ishidao T, et al. Anteriorization of neural fate by inhibitor of beta-catenin and T cell factor (ICAT), a negative regulator of Wnt signaling. Proc Natl Acad Sci USA 2004; 101: 8017-21.
9.
Fang XY, Pan HF, Leng RX, Ye DQ. Long noncoding RNAs: novel insights into gastric cancer. Cancer Letters 2015; 356: 357-66.
10.
Ou MY, Xiao Q, Ju XC, et al. The CTNNBIP1-CLSTN1 fusion transcript regulates human neocortical development. Cell Rep 2021; 35: 109290.
11.
Zhang Z, Jiang W, Hu M, Gao R, Zhou X. MiR-486-3p promotes osteogenic differentiation of BMSC by targeting CTNNBIP1 and activating the Wnt/-catenin pathway. Biochem Biophys Res Commun 2021; 566: 59-66.
12.
Chang JM, Tsai AC, Huang WR, Tseng RC. The alteration of CTNNBIP1 in lung cancer. Int J Mol Sci 2019; 20: 5684.
13.
Bi W, Huang J, Nie C, et al. CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of -catenin pathway. J Exp Clin Cancer Res 2018; 37: 275.
14.
Kosari-Monfared M, Nikbakhsh N, Fattahi S, et al. CTNNBIP1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma. J Cell Physiol 2019; 234: 2895-904.
15.
Rothzerg E, Xu J, Wood D, Kõks S. 12 Survival-related differentially expressed genes based on the TARGET-osteosarcoma database. Exp Biol Med 2021; 246: 2072-81.
16.
Yang J, Zhang A, Luo H, Ma C. Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma. Sci Rep 2022; 12: 1279.
17.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-50.
18.
Wang Y, Liu S, Chen Y, Zhu B, Xing Q. Survival prognosis, tumor immune landscape, and immune responses of PPP1R18 in kidney renal clear cell carcinoma and its potentially double mechanisms. World J Oncol 2022; 13: 27-37.
19.
Maimaiti A, Tuersunniyazi A, Meng X, et al. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma. Front Genet 2022; 13: 872186.
20.
Meng S, Liu Y, Wang X, et al. The prognostic value and biological significance of gap junction beta protein 2 (GJB2 or Cx26) in cervical cancer. Front Oncol 2022; 12: 907960.
21.
Gao Y, Li JY, Mao JY, Zhou JF, Jiang L, Li XP. Comprehensive analysis of CRIP1 expression in acute myeloid leukemia. Front Genet 2022; 13: 923568.
22.
Zhang S, Zhang W, Zhang J. 8-Gene signature related to CD8(+) T cell infiltration by integrating single-cell and bulk RNA-sequencing in head and neck squamous cell carcinoma. Front Genet 2022; 13: 938611.
23.
Lin Z, Wang R, Huang C, et al. Identification of an immune-related prognostic risk model in glioblastoma. Front Genet 2022; 13: 926122.
24.
Xu JL. Wilms tumor 1-associated protein expression is linked to a T-cell-inflamed phenotype in pancreatic cancer. Dig Dis Sci 2022; 68: 831-40.
25.
Reinhold WC, Sunshine M, Liu H, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012; 72: 3499-511.
26.
Ma F, Li X, Fang H, Jin Y, Sun Q, Li X. Prognostic value of ANXA8 in gastric carcinoma. J Cancer 2020; 11: 3551-8.
27.
Cai X, Qiu W, Qian M, et al. A candidate prognostic biomarker complement factor I promotes malignant progression in glioma. Front Cell Develop Biol 2020; 8: 615970.
28.
Kui XY, Gao Y, Liu XS, et al. Comprehensive analysis of SLC17A9 and its prognostic value in hepatocellular carcinoma. Front Oncol 2022; 12: 809847.
29.
Wei S, Yu Z, Shi R, et al. GPX4 suppresses ferroptosis to promote malignant progression of endometrial carcinoma via transcriptional activation by ELK1. BMC Cancer 2022; 22: 881.
30.
Guo Z, Tang Y, Fu Y, Wang J. Decreased expression of STAT5A predicts poor prognosis in osteosarcoma. Pathol Res Pract 2019; 215: 519-24.
31.
Yin CD, Hou YL, Liu XR, et al. Development of an immune-related prognostic index associated with osteosarcoma. Bioengineered 2021; 12: 172-82.
32.
Yang M, Cao Y, Wang Z, Zhang T, Hua Y, Cai Z. Identification of two immune subtypes in osteosarcoma based on immune gene sets. Int Immunopharmacol 2021; 96: 107799.
33.
Chen L, Ke X. MMP7 as a potential biomarker of colon cancer and its prognostic value by bioinformatics analysis. Medicine 2021; 100: e24953.
34.
Wu F, Xu J, Jin M, et al. Development and verification of a hypoxic gene signature for predicting prognosis, immune microenvironment, and chemosensitivity for osteosarcoma. Front Mol Biosci 2021; 8: 705148.
35.
Filaci G, Rizzi M, Setti M, et al. Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. Ann NY Acad Sci 2005; 1050: 115-23.
36.
Sha S, Si L, Wu X, et al. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer. Front Immunol 2022; 13: 922780.
37.
Chen R, Wu W, Chen SY, et al. A Pan-cancer analysis reveals CLEC5A as a biomarker for cancer immunity and prognosis. Front Immunol 2022; 13: 831542.
38.
Wang B, Liu B, Luo Q, et al. PANK1 associates with cancer metabolism and immune infiltration in clear cell renal cell carcinoma: a retrospective prognostic study based on the TCGA database. Transl Cancer Res 2022; 11: 2321-37.
39.
Cheng Q, Li L, Yu M. Construction and validation of a transcription factors-based prognostic signature for ovarian cancer. J Ovarian Res 2022; 15: 29.
40.
Huang X, Wang L, Guo H, Zhang W, Shao Z. Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma. Theranostics 2022; 12: 5877-87.
41.
Ma Y, Tong C, Xu M, He H, Chen C. Bioinformatics analysis reveals an association between autophagy, prognosis, tumor microenvironment, and immunotherapy in osteosarcoma. J Oncol 2022; 2022: 4220331.
42.
Lei M, Luo C, Zhang J, Cao W, Ge J, Zhao M. A m(6)A methyltransferase-mediated immune signature determines prognosis, immune landscape and immunotherapy efficacy in patients with lung adenocarcinoma. Cell Oncol 2022; 45: 931-49.
43.
Chen Y, Ji H, Liu S, Xing Q, Zhu B, Wang Y. Survival prognosis, tumor immune landscape, and immune responses of ADAMTS14 in clear cell renal cell carcinoma and its potential mechanisms. Front Immunol 2022; 13: 790608.
44.
Ding X, Liu H, Yuan Y, Zhong Q, Zhong X. Roles of GFPT2 expression levels on the prognosis and tumor microenvironment of colon cancer. Front Oncol 2022; 12: 811559.
45.
Huang R, Li L, Wang Z, Shen K. A systemic pan-cancer analysis of MPZL3 as a potential prognostic biomarker and its correlation with immune infiltration and drug sensitivity in breast cancer. Front Oncol 2022; 12: 901728.
46.
Chen Y, Zhou M, Gu X, Wang L, Wang C. High expression of TACC3 is associated with the poor prognosis and immune infiltration in lung adenocarcinoma patients. Dis Markers 2022; 2022: 8789515.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
